If you could vote on Brexit now which option would you choose?
   

Vir, WuXi Biologics terminate COVID antibody pact as US rollout faces uncertain future


The U.S. distribution of Vir Biotechnology’s GSK-partnered COVID-19 antibody has been put on hold for more than a month. Now, a collaborator in the therapy wants out. WuXi Biologics has returned China rights to Vir’s COVID antibody, sotrovimab, the latter company said in a securities filing (PDF) published Friday. As part of the termination agreement, Vir will pay WuXi Bio $7 million to cover the Chinese CDMO’s development expenses. If sotrovimab is eventually approved in China, Vir is also on the hook to pay WuXi Bio tiered royalties on sales ranging from low single-digit percentages to low double-digit percentages, the company said.

FiercePharma - May 23, 2022

View the full story here: https://www.fiercepharma.com/pharma/vir-wuxi-biologics-terminate-covid-antibody-pact-just-us-rollout-pauses